Rivaroxaban for treatment of pediatric venous thromboembolism: An Einstein-Jr phase 3 dose-exposure-response evaluation

G. Young, A.W.A. Lensing, P. Monagle, C. Male, K. Thelen, S. Willmann, J.S. Palumbo, R. Kumar, I. Nurmeev, K. Hege, F. Bajolle, P. Connor, H.L. Hooimeijer, M. Torres, A.K.C. Chan, G. Kenet, S. Holzhauer, A. Santamaria, P. Amedro, J. Beyer-WestendorfI. Martinelli, M.P. Massicotte, W.T. Smith, S.D. Berkowitz, S. Schmidt, V. Price, M.H. Prins, D. Kubitza, P.h.a.s.e. EINSTEIN-Jr, EINSTEIN-Jr Phase 3 Investigators

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1672-1685
Number of pages14
JournalJournal of Thrombosis and Haemostasis
Volume18
Issue number7
DOIs
Publication statusPublished - 1 Jul 2020

Keywords

  • anticoagulation
  • antithrombotic therapy
  • atrial-fibrillation
  • bodyweight-adjusted dosing
  • children
  • definition
  • disease
  • pediatric patients
  • pharmacokinetics
  • rivaroxaban
  • suspension
  • thrombosis
  • venous thromboembolism
  • DEFINITION
  • THROMBOSIS
  • ATRIAL-FIBRILLATION
  • CHILDREN
  • ANTITHROMBOTIC THERAPY
  • DISEASE

Cite this